Welcome to our dedicated page for Altimmune news (Ticker: ALT), a resource for investors and traders seeking the latest updates and insights on Altimmune stock.
Altimmune, Inc. (Nasdaq: ALT) generates a steady flow of news as a late clinical-stage biopharmaceutical company developing peptide-based therapeutics for liver, metabolic and cardiometabolic diseases. Most company updates center on its lead investigational medicine, pemvidutide, a balanced 1:1 glucagon/GLP-1 dual receptor agonist in development for metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), alcohol-associated liver disease (ALD) and obesity.
News coverage of ALT frequently highlights clinical trial milestones. Altimmune issues detailed press releases on the IMPACT Phase 2b trial in MASH, including 24-week and 48-week topline data, changes in non-invasive tests of fibrosis and hepatic inflammation, and AI-based digital pathology analyses of liver biopsies. Additional updates describe progress in the RECLAIM Phase 2 trial in AUD and the RESTORE Phase 2 trial in ALD, including enrollment status and expected timelines for topline results.
Investors and followers of ALT stock also see regulatory and scientific news, such as Fast Track designations for pemvidutide in MASH and AUD, Breakthrough Therapy Designation for MASH, and publication of IMPACT trial data in peer-reviewed journals. Presentations at major medical meetings, including late-breaking oral and poster sessions at The Liver Meeting hosted by the American Association for the Study of Liver Diseases (AASLD), are common subjects of company announcements.
Altimmune’s news flow further includes corporate and financial updates. These range from quarterly financial results and business updates to CEO succession plans, executive appointments, term loan amendments and at-the-market equity offering arrangements disclosed in SEC filings and companion press releases. For anyone tracking ALT, this news page brings together clinical, regulatory, scientific and corporate developments in one place, making it easier to follow how Altimmune’s programs and capital strategy evolve over time.
Altimmune (Nasdaq: ALT) closed a registered direct offering raising approximately $75 million gross through sale of 17,045,454 shares of common stock (or pre-funded warrants) on Jan 29, 2026. Proceeds will fund the planned Phase 3 pemvidutide trial for MASH, plus working capital and general corporate purposes. The pre-funded warrants are exercisable immediately at $0.001 per share. Titan Partners acted as sole placement agent; the offering was made from an effective shelf registration declared effective Dec 5, 2025.
Altimmune (Nasdaq: ALT) priced a registered direct offering expected to raise approximately $75 million of gross proceeds through the sale of 17,045,454 common shares (or pre-funded warrants), with closing expected on or about January 29, 2026.
Altimmune said it intends to use net proceeds to fund preparation for its planned Phase 3 trial in metabolic dysfunction-associated steatohepatitis (MASH), plus working capital and general corporate purposes. The company cited Phase 2b 48-week topline data and a Breakthrough Therapy Designation from the U.S. FDA for pemvidutide.
Altimmune (NASDAQ: ALT) announced that the U.S. Food and Drug Administration granted Breakthrough Therapy Designation for pemvidutide to treat metabolic dysfunction-associated steatohepatitis (MASH) on January 5, 2026. The designation was based on 24-week IMPACT Phase 2b data showing statistically significant MASH resolution without worsening fibrosis and early improvements in liver fat and non-invasive fibrosis/inflammation tests.
Altimmune reported 48-week topline data in December 2025 showing further statistically significant improvements in ELF and LSM, continued weight loss at the 1.8 mg dose, and a favorable tolerability profile. The company and FDA aligned on registrational Phase 3 parameters and plan a 52-week, biopsy-endpoint Phase 3 using multiple doses and AIM-MASH AI Assist; European scientific advice will also be sought.
Altimmune (Nasdaq: ALT) reported positive 48-week topline results from the IMPACT Phase 2b trial of pemvidutide in MASH patients on Dec 19, 2025. Both 1.2 mg and 1.8 mg doses produced statistically significant improvements in noninvasive fibrosis markers versus placebo, including ELF (‑0.49 and ‑0.58 vs +0.16; p<0.0001) and LSM (‑3.04 and ‑3.97 vs ‑0.03; p<0.05/0.001).
Additional 48-week highlights: liver fat down 45.2% and 54.7% (vs 8.2% placebo), ALT reductions ~‑38 IU/L (vs ‑10.3), weight loss 4.5% and 7.5% (vs 0.2%), low discontinuations, and FDA End‑of‑Phase 2 alignment to advance to a registrational Phase 3 planned for 2026.
Altimmune (Nasdaq: ALT) announced a CEO succession: Jerry Durso will become President and Chief Executive Officer effective January 1, 2026, while retaining his role as Chairman. Vipin Garg, Ph.D. will step down as CEO and serve as an advisor through June 30, 2026.
The company highlighted progress of its lead candidate, pemvidutide (dual glucagon/GLP-1 agonist), described as Phase 3 ready for MASH. Altimmune expects to hold an End-of-Phase 2 meeting with the FDA later this quarter and to report 48-week IMPACT Phase 2b data before year-end, including NIT, weight loss, and safety data.
Altimmune (NASDAQ: ALT) announced that its management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference.
The session is scheduled for Wednesday, December 3, 2025 at 2:30 p.m. ET and will be available via webcast. Investors can access the webcast through the Events section of Altimmune's website.
Altimmune (NASDAQ: ALT) announced publication in The Lancet of 24-week IMPACT Phase 2b results for pemvidutide in MASH and a late-breaking oral presentation at AASLD The Liver Meeting® 2025 on Nov 11, 2025.
Key 24-week findings: MASH resolution occurred in 58% (1.2 mg) and 52% (1.8 mg) versus 20% for placebo; liver fat normalization reached 31% and 44% versus 4% for placebo; mean weight reductions were −4.8% and −5.8% versus −0.5% for placebo. Multiple non-invasive tests (MRI-PDFF, FibroScan, cT1, ELF, PRO-C3, FAST) showed consistent improvements and liver stiffness fell by −3.7 kPa and −2.2 kPa for active doses. Safety/tolerability were described as favorable with low discontinuation rates. Altimmune said longer-term NIT and weight-loss readouts will be provided in Q4 2025.
Altimmune (Nasdaq: ALT) reported AI-based digital pathology analysis from the IMPACT Phase 2b pemvidutide trial in MASH showing significant fibrosis reductions vs placebo at 24 weeks.
Key results: 31% of patients on pemvidutide 1.8 mg achieved ≥60% total fibrosis area reduction (n=85) vs 8% placebo (n=86; p=0.0003); early fibrosis ≥60% reduction: 34% (1.8 mg) vs 9% placebo (p<0.0001); advanced fibrosis ≥60% reduction: 27% (1.8 mg) vs 11% placebo (p=0.0063). Non-invasive tests including PRO-C3:CTX-III ratio and PRO-C6 also improved.
Altimmune (Nasdaq: ALT) reported Q3 2025 corporate and financial updates on November 6, 2025. Key points: $210.8M cash, cash equivalents and short-term investments as of September 30, 2025 (about +60% vs. Dec 31, 2024); net loss of $19.0M (−$0.21 per share) for Q3 2025; R&D expense of $15.0M in Q3 2025. Important clinical milestones: an End-of-Phase 2 meeting with FDA scheduled Q4 2025 for pemvidutide MASH and 48-week IMPACT data expected before year-end 2025. Corporate: amended Hercules facility to $125M with an additional $20M draw, and three senior hires (CMO, CCO, CLO).
Altimmune (Nasdaq: ALT) said company management will attend two investor conferences in November 2025: a Stifel 2025 Healthcare Conference fireside chat on November 12, 2025 at 10:00 a.m. ET, and a Jefferies Global Healthcare Conference fireside chat on November 20, 2025 at 9:30 a.m. GMT. Management will be available for one-on-one meetings. Both sessions will be webcast and accessible via the Events section of the company's website.